FDA Panel Gives Thumbs Down to Novel Strategy for Switching Breast Cancer Therapy
Summary
Panelists conflicted about positive trial's ability to validate biomarker-guided switching
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.